Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Source: onclive.com
L Mind Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from L Mind Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In L Mind Study Today - Breaking & Trending Today
Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study
Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Source: onclive.com